1
40
2
-
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
2020 Oncology List
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Oncology 2020 List
URL Address
<a href="http://doi.org/10.1089/cap.2019.0164" target="_blank" rel="noreferrer noopener">http://doi.org/10.1089/cap.2019.0164</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antipsychotic Medications Palliate Symptoms in Children with Cancer
Publisher
An entity responsible for making the resource available
Journal of Child and Adolescent Psychopharmacology
Date
A point or period of time associated with an event in the lifecycle of the resource
2020
Subject
The topic of the resource
psycho-oncology; liaison; olanzapine; risperidone
Creator
An entity primarily responsible for making the resource
Peled O; Lavan O; Stein J; Vinograd I; Yahel A; Valevski A; Weizman A; Kimmel-Tamir E; Apter A; Fennig S; Yaniv I; Bernfeld Y; Benaroya-Milshtein N
Description
An account of the resource
Objectives: The present study characterized the psychiatric diagnoses and symptoms that led to the administration of antipsychotic medications in children and adolescents with cancer, and to evaluate the benefits and tolerability of these drugs in a large hospital-based pediatric hematology-oncology practice. Methods: Efficacy and adverse effects of two second-generation antipsychotics were retrospectively analyzed in 43 patients 2.9-19.6 (mean 12.1) years of age. The Clinical Global Impression-Severity (CGI-S) Scale and Improvement (CGI-I) Scale were used to evaluate psychiatric symptom severity before and following treatment, while the incidence of side effects and drug-drug interactions were collected from medical records. Results: Olanzapine was administered to 58% of patients and risperidone to 42%; the choice of drug was at the discretion of the treating psychiatrist. The common psychiatric diagnoses among these patients included adjustment disorder (37%) and medication-induced psychiatric disorders (23%). The most common psychiatric-medical symptoms included irritability/agitation (79%) and depressed mood (74%). CGI-S improved significantly (p < 0.001) between assessments, with no statistically significant difference between olanzapine- and risperidone-treated patients. CGI-I scores at reassessment indicated superiority of olanzapine as compared with risperidone. Adverse effects of treatment were mild. Conclusions: Olanzapine and risperidone can be well tolerated and ameliorate severe psychiatric-medical symptoms in children and adolescents with cancer. The potential palliative benefits of these second-generation antipsychotics (e.g., rapid onset of action, antiemesis, sedation, and appetite stimulation) increase the utility of their use in children treated in oncology and bone marrow transplant units.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1089/cap.2019.0164" target="_blank" rel="noreferrer noopener">10.1089/cap.2019.0164</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2020
Apter A
Benaroya-Milshtein N
Bernfeld Y
Fennig S
Journal Of Child And Adolescent Psychopharmacology
Kimmel-Tamir E
Lavan O
liaison
olanzapine
Oncology 2020 List
Peled O
Psycho-Oncology
Risperidone
Stein J
Valevski A
Vinograd I
Weizman A
Yahel A
Yaniv I
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1089/cap.1990.1.237" target="_blank" rel="noreferrer">http://doi.org/10.1089/cap.1990.1.237</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
The opiate hypothesis in autism and self-injury
Publisher
An entity responsible for making the resource available
Journal Of Child And Adolescent Psychopharmacology
Date
A point or period of time associated with an event in the lifecycle of the resource
1990
Subject
The topic of the resource
Pain Measurement; Analgesics; Pain; Pain Threshold; Naloxone; Naltrexone; Autistic disorder; Self-Injurious behavior; Opioid; Autism; Self Mutiliation
Creator
An entity primarily responsible for making the resource
Sandman CA
Description
An account of the resource
The opiate hypothesis maintains that patients engage in self-injurious behavior (SIB) either because they are partially analgesic (pathologically altered pain threshold) or because SIB supplies a "fix" for an addicted endogenous opiate system. The finding that opiate antogonists attenuate SIB is the strongest evidence for the opiate hypothesis. Most of the patients who had been administered opiate receptor antagonists for treatment of self-injurious behavior also had autistic disorder. Initial studies with naloxone, an injectable opiate blocker, reported positive effects in 8 (with robust effects in 6) of the 10 patients treated. Positive results were reported in studies with orally administered naltrexone in 38 of 45 autistic patients, including 24 of those 28 with SIB. Generally, the effective dose range for naltrexone is 0.5-1.5 mg/kg, but patients with high-frequency SIB typically responded best to the higher doses. Although the findings suggest a role of opiates in SIB, the database is very small and the studies vary widely in dimensions of dose, duration and method of observation, experimental controls, duration of treatment, and the age, gender, and diagnosis of patients treated. At this time, opiate blockers appear to be the only treatment option for some SIB patients who fail to respond to other treatments. It is unclear whether these treatments would help autistic patients who do not exhibit SIB or whether they would help nonautistic patients who demonstrate SIB, including individuals with Lesch-Nyhan disease, phenylketonuria, border-line personality, or major depression.
1990
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1089/cap.1990.1.237" target="_blank" rel="noreferrer">10.1089/cap.1990.1.237</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
1990
Analgesics
Autism
Autistic disorder
Backlog
Journal Article
Journal Of Child And Adolescent Psychopharmacology
Naloxone
Naltrexone
Opioid
Pain
Pain Measurement
Pain Threshold
Sandman CA
Self Mutiliation
Self-Injurious behavior